A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
Introduction. In recent years, due to the progressive increase in the prevalence of castration-resistant prostate cancer (CRPC), the question of the sequence of prescription drugs is becoming more acute.Objective is to compare the effectiveness of various regimens of treatment of CRPC with the use o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-05-01
|
| Series: | Андрология и генитальная хирургия |
| Subjects: | |
| Online Access: | https://agx.abvpress.ru/jour/article/view/279 |
| _version_ | 1797883561519349760 |
|---|---|
| author | A. V. Kondrashina L. M. Rapoport E. A. Bezrukov R. B. Sukhanov G. E. Krupinov |
| author_facet | A. V. Kondrashina L. M. Rapoport E. A. Bezrukov R. B. Sukhanov G. E. Krupinov |
| author_sort | A. V. Kondrashina |
| collection | DOAJ |
| description | Introduction. In recent years, due to the progressive increase in the prevalence of castration-resistant prostate cancer (CRPC), the question of the sequence of prescription drugs is becoming more acute.Objective is to compare the effectiveness of various regimens of treatment of CRPC with the use of abirateron acetate and docetaxel. Materials and methods. The analysis included 83 patients with CRPC, which were divided into 2 groups depending on the sequence of appointment of abiraterone acetate and docetaxel.Results. Differences in the level of 2-year survival were statistically insignificant (73,2 % in the 1st group, 69 % in the 2nd group), and 3-year survival significantly differed: in the 1st group – 29,3 %, in the 2nd group – 16,7 % (p <0.05). Due to the short duration of the analysis, 5-year survival was not evaluated. The average value of overall survival in the appointment of the first docetaxel, then abiraterone acetate was 32 months, with the reverse regimen (abiraterone acetate, then docetaxel) – 27 months (p = 0.01).Conclusion. The scheme with the appointment of the first docetaxel, then abiraterone acetate is more effective from the point of view of affect on overall and 3-year survival in patients with CRPC. |
| first_indexed | 2024-04-10T03:52:29Z |
| format | Article |
| id | doaj.art-5220412a25bc4a9a979518f6beb29d07 |
| institution | Directory Open Access Journal |
| issn | 2070-9781 |
| language | Russian |
| last_indexed | 2024-04-10T03:52:29Z |
| publishDate | 2018-05-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Андрология и генитальная хирургия |
| spelling | doaj.art-5220412a25bc4a9a979518f6beb29d072023-03-13T07:15:09ZrusABV-pressАндрология и генитальная хирургия2070-97812018-05-01191596210.17650/2070-9781-2018-19-1-59-62261A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCERA. V. Kondrashina0L. M. Rapoport1E. A. Bezrukov2R. B. Sukhanov3G. E. Krupinov4I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaIntroduction. In recent years, due to the progressive increase in the prevalence of castration-resistant prostate cancer (CRPC), the question of the sequence of prescription drugs is becoming more acute.Objective is to compare the effectiveness of various regimens of treatment of CRPC with the use of abirateron acetate and docetaxel. Materials and methods. The analysis included 83 patients with CRPC, which were divided into 2 groups depending on the sequence of appointment of abiraterone acetate and docetaxel.Results. Differences in the level of 2-year survival were statistically insignificant (73,2 % in the 1st group, 69 % in the 2nd group), and 3-year survival significantly differed: in the 1st group – 29,3 %, in the 2nd group – 16,7 % (p <0.05). Due to the short duration of the analysis, 5-year survival was not evaluated. The average value of overall survival in the appointment of the first docetaxel, then abiraterone acetate was 32 months, with the reverse regimen (abiraterone acetate, then docetaxel) – 27 months (p = 0.01).Conclusion. The scheme with the appointment of the first docetaxel, then abiraterone acetate is more effective from the point of view of affect on overall and 3-year survival in patients with CRPC.https://agx.abvpress.ru/jour/article/view/279castration-resistant prostate cancerabiraterone acetatedocetaxeltreatment regimenoverall survival |
| spellingShingle | A. V. Kondrashina L. M. Rapoport E. A. Bezrukov R. B. Sukhanov G. E. Krupinov A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER Андрология и генитальная хирургия castration-resistant prostate cancer abiraterone acetate docetaxel treatment regimen overall survival |
| title | A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER |
| title_full | A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER |
| title_fullStr | A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER |
| title_full_unstemmed | A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER |
| title_short | A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER |
| title_sort | comparison of the effectiveness of different treatment regimens with the use of abiraterone acetate and docetaxel in patients with castration resistant prostate cancer |
| topic | castration-resistant prostate cancer abiraterone acetate docetaxel treatment regimen overall survival |
| url | https://agx.abvpress.ru/jour/article/view/279 |
| work_keys_str_mv | AT avkondrashina acomparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT lmrapoport acomparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT eabezrukov acomparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT rbsukhanov acomparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT gekrupinov acomparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT avkondrashina comparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT lmrapoport comparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT eabezrukov comparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT rbsukhanov comparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer AT gekrupinov comparisonoftheeffectivenessofdifferenttreatmentregimenswiththeuseofabirateroneacetateanddocetaxelinpatientswithcastrationresistantprostatecancer |